Enzyme-Responsive Mesoporous Ruthenium for Combined Chemo-Photothermal Therapy of Drug-Resistant Bacteria

The rapid mutation of drug-resistant bacteria and the serious lag of development of new antibiotics necessitate research on novel antibacterial agents. Nanomaterials with unique size effect and antibacterial mechanism could serve as an alternative for antibiotics, since they showed low possibility to develop drug-resistant bacteria. Here, an enzyme-responsive nanosystem, AA@Ru@HA-MoS2, with a synergistic chemo-photothermal therapy function is proposed to treat bacterial infections. Mesoporous ruthenium nanoparticles (Ru NPs) were used as nanocarriers, loading prodrug ascorbic acid (AA) and encapsulated by hyaluronic acid (HA). Then, molybdenum disulfide (MoS2) precoated with ciprofloxacin was used as a catalyst with targeting effect binding to the outer surface. When the nanosystem gathered at the infection site, Hyal secreted by bacteria could degrade the HA capping and trigger the release of AA and then generated hydroxyl radicals (•OH) in situ by the catalysis of MoS2. In addition, taking advantage of the good photothermal property of Ru NPs, combined chemo-photothermal antibacterial therapy could be achieved. The nanosystem exhibited potent bactericidal activity against drug-resistant Gram-positive and Gram-negative bacteria. Furthermore, it could break down the biofilm, inhibit the contained bacteria, and prevent the formation of a new biofilm. The in vivo bacterium-infected model also proved accelerated wound healing. The study showed a high potential of AA@Ru@HA-MoS2 as a novel enzyme-responsive nanosystem for combating drug-resistant bacterial infection.